Safety and Efficacy of 120mg and 240mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV-co-infected patients. A multinational, randomised, parallel group, open-label trial.

Trial Profile

Safety and Efficacy of 120mg and 240mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV-co-infected patients. A multinational, randomised, parallel group, open-label trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2015

At a glance

  • Drugs Faldaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms STARTVerso-4; STARTVerso4
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Sep 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 13 Apr 2014 Results assessing benefit of extended treatment in patients with hepatitis C RNA less than 25 IU/mL at week 4 presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top